ACTRN12620000447954
Withdrawn
未知
se of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- COVID-19
- Sponsor
- Royal Brisbane & Women's Hospital
- Enrollment
- 150
- Status
- Withdrawn
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients admitted to ICU at the Royal Brisbane \& Women's Hospital with suspected or proven severe COVID\-19 infection, prescribed hydroxychloroquine as part of their routine management.
Exclusion Criteria
- •Individuals aged \<18 years old.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Assessment of Memantine Drug Levels in Blood Among Indian Patients with Brain Metastases Treated with Radiation TherapyHealth Condition 1: C719- Malignant neoplasm of brain, unspecifiedCTRI/2024/04/066217Amrita School of Pharmacy
Completed
Phase 3
Therapeutic drug monitoring-based dose optimisation of piperacillin in patients with severe sepsis or septic shock to investigate effects on organ functions and survival: a prospective, multicenter, randomized controlled trialR65.1R57.2Systemic Inflammatory Response Syndrome of infectious origin with organ failureSeptic shockDRKS00011159Friedrich-Schiller-Universität Jena254
Recruiting
Not Applicable
Influence of therapeutic drug monitoring (TDM) on the tolerability and efficacy of 5-FU-containing chemotherapy in patients with colorectal carcinoma in the colorectal center at St.-Franziskus-Hospital Münster: a prospective, monocentric observational study.C18Malignant neoplasm of colonDRKS00026926St. Franziskus-Hospital GmbH50
Active, not recruiting
Not Applicable
Effectiveness of theraPeutic drug mOnitoring (TDM) on mucosal and transmural healing in pediatric patients with moderate to severe luminal CroHn’s disease newly receiving Remsima(infliximab): EPOCH studyDiseases of the digestive systemKCT0005190Samsung Medical Center116
Active, not recruiting
Phase 1
Measurement of the blood concentration of the antibiotic piperacillin and individual drug dosage in patients with febrile neutropenia after chemotherapyPatients with febrile neutropenia after myelo-suppressive chemotherapy treated with piperacillin/tazobactamTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2016-002388-33-DEFriedrich-Schiller-University Jena208